JP2024512767A5 - - Google Patents

Info

Publication number
JP2024512767A5
JP2024512767A5 JP2023560831A JP2023560831A JP2024512767A5 JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5 JP 2023560831 A JP2023560831 A JP 2023560831A JP 2023560831 A JP2023560831 A JP 2023560831A JP 2024512767 A5 JP2024512767 A5 JP 2024512767A5
Authority
JP
Japan
Application number
JP2023560831A
Other languages
Japanese (ja)
Other versions
JPWO2022212894A5 (https=
JP2024512767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023133 external-priority patent/WO2022212894A1/en
Publication of JP2024512767A publication Critical patent/JP2024512767A/ja
Publication of JPWO2022212894A5 publication Critical patent/JPWO2022212894A5/ja
Publication of JP2024512767A5 publication Critical patent/JP2024512767A5/ja
Pending legal-status Critical Current

Links

JP2023560831A 2021-04-02 2022-04-01 Rasの阻害方法 Pending JP2024512767A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170292P 2021-04-02 2021-04-02
US63/170,292 2021-04-02
US202163192843P 2021-05-25 2021-05-25
US63/192,843 2021-05-25
PCT/US2022/023133 WO2022212894A1 (en) 2021-04-02 2022-04-01 Methods for inhibiting ras

Publications (3)

Publication Number Publication Date
JP2024512767A JP2024512767A (ja) 2024-03-19
JPWO2022212894A5 JPWO2022212894A5 (https=) 2025-04-08
JP2024512767A5 true JP2024512767A5 (https=) 2025-04-08

Family

ID=83456876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560831A Pending JP2024512767A (ja) 2021-04-02 2022-04-01 Rasの阻害方法

Country Status (12)

Country Link
US (1) US20240108630A1 (https=)
EP (1) EP4320143A4 (https=)
JP (1) JP2024512767A (https=)
KR (1) KR20240004436A (https=)
AU (1) AU2022249177A1 (https=)
BR (1) BR112023020182A2 (https=)
CA (1) CA3214155A1 (https=)
CR (1) CR20230500A (https=)
IL (1) IL307396A (https=)
MX (1) MX2023011608A (https=)
TW (1) TW202308632A (https=)
WO (1) WO2022212894A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
CN119301132A (zh) * 2022-06-01 2025-01-10 豪夫迈·罗氏有限公司 用于治疗癌症的卤代吲哚大环化合物
CN117720556A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物及其制备方法和用途
EP4582426A4 (en) * 2022-09-19 2025-12-24 Adlai Nortye Biopharma Co Ltd PAN-KRAS INHIBITOR COMPOUND
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
WO2024104364A1 (zh) * 2022-11-16 2024-05-23 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN117534684A (zh) * 2022-11-29 2024-02-09 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
IL322278A (en) * 2023-02-06 2025-09-01 Bicara Therapeutics Inc Combined therapy and related methods
CR20250329A (es) 2023-02-14 2025-09-12 Hoffmann La Roche Compuestos tricíclicos para el tratamiento del cáncer
WO2024187174A2 (en) * 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
EP4687905A1 (en) * 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
WO2025051241A1 (zh) * 2023-09-06 2025-03-13 劲方医药科技(上海)股份有限公司 大环化合物及其抗体-药物偶联物
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025087431A1 (zh) * 2023-10-27 2025-05-01 贝达药业股份有限公司 泛-kras抑制剂及其在医药上的应用
WO2025093625A1 (en) * 2023-11-01 2025-05-08 F. Hoffmann-La Roche Ag Macrocycle compounds for the treatment of cancer
WO2025119392A1 (zh) * 2023-12-08 2025-06-12 正大天晴药业集团股份有限公司 含有酰胺取代的大环类化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025193628A2 (en) * 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025252241A1 (zh) * 2024-06-07 2025-12-11 杭州和正医药有限公司 一种大环衍生物及其用途
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015745A1 (en) * 2024-07-11 2026-01-15 Treeline Biosciences, Inc. Macrocyclic ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR20210116479A (ko) * 2018-12-21 2021-09-27 레볼루션 메디슨즈, 인크. 공동 결합에 참여하는 화합물 및 그의 용도
MX2023003060A (es) * 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13135U (https=)